Skye Bioscience, Inc. filed its 10-K on Mar 31, 2023 for the period ending Dec 31, 2022. In this report its auditor, Marcum LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.32 USD | -2.16% | -2.83% | +316.18% |
May. 10 | Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 23 | Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+316.18% | 318M | |
+55.55% | 59.28B | |
+43.74% | 40.94B | |
-4.71% | 40.17B | |
-5.56% | 28.69B | |
+13.76% | 26.63B | |
-22.00% | 18.89B | |
+31.50% | 12.46B | |
+2.16% | 12.42B | |
+25.70% | 12.26B |
- Stock Market
- Equities
- EMBI Stock
- News Skye Bioscience, Inc.
- Skye Bioscience, Inc. Auditor Raises 'Going Concern' Doubt